Identification

Name
Tamsulosin
Accession Number
DB00706  (APRD00036)
Type
Small Molecule
Groups
Approved, Investigational
Description

Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.

Structure
Thumb
Synonyms
  • (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
  • 5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
  • Tamsulosin
  • Tamsulosina
  • Tamsulosine
  • Tamsulosinum
External IDs
HGP-0412 / HIP-1402 / HIP1402 / LY 253351 / Y 617 / YM 12617-1 / YM-617
Product Ingredients
IngredientUNIICASInChI Key
Tamsulosin Hydrochloride11SV1951MR106463-17-6ZZIZZTHXZRDOFM-XFULWGLBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlomaxCapsule.4 mg/1OralBoehringer Ingelheim1997-09-122017-04-20Us
FlomaxCapsule.4 mg/1OralCardinal Health1997-09-122017-10-31Us
FlomaxCapsule.4 mg/1OralStat Rx USA1997-09-122018-02-08Us
FlomaxCapsule.4 mg/1OralRemedy Repack2017-05-15Not applicableUs
FlomaxCapsule.4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-05-132018-04-05Us
FlomaxCapsule, extended release0.4 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1998-06-192009-08-27Canada
FlomaxCapsule.4 mg/1OralBoehringer Ingelheim1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralPhysicians Total Care, Inc.2001-08-28Not applicableUs
FlomaxCapsule.4 mg/1OralRemedy Repack2011-03-302017-03-09Us
FlomaxCapsule.4 mg/1Oralbryant ranch prepack1997-09-12Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tamsulosin CRTablet, extended release0.4 mgOralApotex Corporation2012-02-09Not applicableCanada
Ava-tamsulosin CRTablet, extended release0.4 mgOralAvanstra Inc2011-09-192014-08-21Canada
Jamp-tamsulosinCapsule, extended release0.4 mgOralJamp Pharma Corporation2010-06-162012-07-05Canada
Mylan-tamsulosinCapsule, extended release0.4 mgOralMylan Pharmaceuticals2007-08-162017-01-09Canada
Ran-tamsulosinCapsule, extended release0.4 mgOralRanbaxy Inc.2007-08-152012-06-13Canada
Ratio-tamsulosinCapsule, extended release0.4 mgOralTeva2007-04-27Not applicableCanada
Tamsulosin HydrochlorideCapsule.4 mg/1OralMylan Institutional2010-05-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMacleods Pharmaceuticals Limited2017-01-25Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralTeva2010-04-272015-12-31Us00093 7338 01 nlmimage10 642d3229
Tamsulosin HydrochlorideCapsule.4 mg/1OralZydus Pharmaceuticals Usa, Inc.2010-04-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dutasteride and Tamsulosin HydrochlorideTamsulosin Hydrochloride (.4 mg/1) + Dutasteride (.5 mg/1)CapsuleOralPar Pharmaceutical2015-11-18Not applicableUs
Dutasteride and Tamsulosin HydrochlorideTamsulosin Hydrochloride (.4 mg/1) + Dutasteride (.5 mg/1)CapsuleOralPrasco, Laboratories2016-07-01Not applicableUs
Dutasteride and tamsulosin hydrochlorideTamsulosin Hydrochloride (.4 mg/1) + Dutasteride (.5 mg/1)CapsuleOralActavis Pharma Company2016-04-13Not applicableUs
JalynTamsulosin Hydrochloride (.4 mg/1) + Dutasteride (.5 mg/1)CapsuleOralPhysicians Total Care, Inc.2012-05-02Not applicableUs
JalynTamsulosin Hydrochloride (0.4 mg) + Dutasteride (0.5 mg)Capsule, extended releaseOralGlaxosmithkline Inc2011-11-17Not applicableCanada
JalynTamsulosin Hydrochloride (.4 mg/1) + Dutasteride (.5 mg/1)CapsuleOralGlaxosmithkline Inc2010-06-21Not applicableUs00173 0809 61 nlmimage10 d11968cb
International/Other Brands
Betamsal (Hemofarm) / Contiflo XL (Ranbaxy) / Flomaxtra (Astellas) / Harnal D (Astellas) / Maxrin (Square) / Mecir (Boehringer Ingelheim) / Omexel (Astellas) / Omipro (Jelfa) / Omix (Astellas) / Omnic (Astellas Pharma Europe) / Pradif (Boehringer Ingelheim) / Ranomax (Ranbaxy) / Salover (Aversi) / Secotex (Boehringer Ingelheim) / Stronazon (Actavis) / Tamsact (Actavis) / Tamsol (Apex) / Tamsul (Aspen Pharmacare) / Urimax (Celeris)
Categories
UNII
G3P28OML5I
CAS number
106133-20-4
Weight
Average: 408.512
Monoisotopic: 408.171892706
Chemical Formula
C20H28N2O5S
InChI Key
DRHKJLXJIQTDTD-OAHLLOKOSA-N
InChI
InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
IUPAC Name
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide
SMILES
CCOC1=CC=CC=C1OCCN[[email protected]](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O

Pharmacology

Indication

Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)

Structured Indications
Pharmacodynamics

Tamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a racemic mixture of 2 isomers, and is pharmacologically related to doxazocin, prazosin, and terazosin. However, unlike these drugs, tamsulosin has a higher affinity for the alpha-1A- adrenergic receptors, which are located in vascular smooth muscle. Studies show that tamsulosin has about 12 times greater affinity for alpha-1 adrenergic receptors in the prostate than those in the aorta, which may result in a reduced incidence of adverse cardiovascular effects.

Mechanism of action

Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate, and thus decreases urinary outflow resistance in men.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
Absorption

Absorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.

Volume of distribution
  • 16 L [intravenous administration to ten healthy male adults]
Protein binding

94%-99%

Metabolism

Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established.

Route of elimination

Tamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion. On administration of the radiolabeled dose of tamsulosin hydrochloride to four healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours.

Half life

5-7 hours

Clearance
  • 2.88 L/h
Toxicity

LD50 = 650 mg/kg (in rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Tamsulosin can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
AdrafinilTamsulosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Agmatine.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the antihypertensive activities of Tamsulosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Withdrawn
AmibegronTamsulosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tamsulosin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Tamsulosin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazTamsulosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Tamsulosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Tamsulosin is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Amyl Nitrite.Approved
AnisodamineTamsulosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Tamsulosin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tamsulosin.Approved, Investigational
ApraclonidineTamsulosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Aranidipine.Approved, Investigational
ArbutamineTamsulosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTamsulosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Tamsulosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tamsulosin.Approved, Investigational
ArtemetherThe metabolism of Tamsulosin can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Tamsulosin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
AtomoxetineThe metabolism of Tamsulosin can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Tamsulosin.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Tamsulosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Tamsulosin.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Tamsulosin is combined with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of hypotension can be increased when Tamsulosin is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
BevantololBevantolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BitolterolTamsulosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Tamsulosin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BortezomibThe metabolism of Tamsulosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Tamsulosin can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Bretylium.Approved
BrimonidineTamsulosin may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamsulosin.Approved, Investigational
BucindololTamsulosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Bumetanide.Approved
BunazosinTamsulosin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tamsulosin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BupropionThe serum concentration of Tamsulosin can be increased when it is combined with Bupropion.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Candesartan cilexetil.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Captopril.Approved
CarbamazepineThe metabolism of Tamsulosin can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tamsulosin.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Tamsulosin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
CarvedilolTamsulosin may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Tamsulosin can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
CeritinibThe serum concentration of Tamsulosin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Tamsulosin can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe metabolism of Tamsulosin can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Chlorthalidone.Approved
CholecalciferolThe metabolism of Tamsulosin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Tamsulosin can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Cinnarizine.Approved, Investigational
CirazolineTamsulosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe metabolism of Tamsulosin can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Tamsulosin can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolTamsulosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Tamsulosin can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tamsulosin.Approved, Investigational
ClomipramineThe metabolism of Tamsulosin can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineTamsulosin may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
ClotrimazoleThe metabolism of Tamsulosin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Tamsulosin can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Tamsulosin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Tamsulosin can be increased when it is combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Tamsulosin.Approved, Investigational
CrizotinibThe metabolism of Tamsulosin can be decreased when combined with Crizotinib.Approved
CyclandelateThe risk or severity of hypotension can be increased when Tamsulosin is combined with Cyclandelate.Approved
CyclosporineThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
DarifenacinThe metabolism of Tamsulosin can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Darodipine.Experimental
DarunavirThe serum concentration of Tamsulosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Tamsulosin can be increased when it is combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tamsulosin.Approved
DesipramineThe metabolism of Tamsulosin can be decreased when combined with Desipramine.Approved, Investigational
DetomidineTamsulosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineTamsulosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Diclofenamide.Approved, Investigational
DihydroergotamineThe metabolism of Tamsulosin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Tamsulosin can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Tamsulosin can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinTamsulosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dipyridamole.Approved
DobutamineTamsulosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineTamsulosin may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DosulepinThe serum concentration of Tamsulosin can be increased when it is combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Tamsulosin.Approved
DoxycyclineThe metabolism of Tamsulosin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Tamsulosin can be decreased when combined with Dronedarone.Approved
DroxidopaTamsulosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineTamsulosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Efonidipine.Approved, Investigational
EliglustatThe metabolism of Tamsulosin can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin.Approved
EnzalutamideThe serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
EperisoneThe risk or severity of hypotension can be increased when Tamsulosin is combined with Eperisone.Approved, Investigational
EphedrineTamsulosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTamsulosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTamsulosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tamsulosin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Eprosartan.Approved
ErgotamineTamsulosin may decrease the vasoconstricting activities of Ergotamine.Approved
ErythromycinThe metabolism of Tamsulosin can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Etacrynic acid.Approved, Investigational
EthosuximideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Ethosuximide.Approved
EtilefrineTamsulosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
FelodipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tamsulosin.Approved
FenoterolTamsulosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tamsulosin.Approved, Investigational
FluconazoleThe metabolism of Tamsulosin can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Flunarizine.Approved
FluoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of hypotension can be increased when Tamsulosin is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Tamsulosin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolTamsulosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Tamsulosin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Tamsulosin can be increased when combined with Fosphenytoin.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tamsulosin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Tamsulosin is combined with Gallopamil.Investigational
GuanabenzTamsulosin may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineTamsulosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolThe metabolism of Tamsulosin can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tamsulosin.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Tamsulosin.Approved
HexoprenalineTamsulosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTamsulosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tamsulosin.Approved, Investigational
IdelalisibThe serum concentration of Tamsulosin can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tamsulosin.Approved, Investigational
ImatinibThe metabolism of Tamsulosin can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tamsulosin.Investigational
ImipramineThe metabolism of Tamsulosin can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Tamsulosin.Withdrawn
IndinavirThe serum concentration of Tamsulosin can be increased when it is combined with Indinavir.Approved
IndoraminTamsulosin may increase the antihypertensive activities of Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Tamsulosin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tamsulosin.Approved
IsoetarineTamsulosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tamsulosin.Approved, Vet Approved
IsoniazidThe metabolism of Tamsulosin can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineTamsulosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineTamsulosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Tamsulosin can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tamsulosin can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Tamsulosin.Approved
LacidipineTamsulosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Tamsulosin is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tamsulosin.Approved, Investigational
LevodopaTamsulosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tamsulosin.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lidoflazine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Tamsulosin.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Loperamide.Approved
LopinavirThe serum concentration of Tamsulosin can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Tamsulosin can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Tamsulosin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Losartan.Approved
LovastatinThe metabolism of Tamsulosin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Tamsulosin can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Tamsulosin can be decreased when combined with Lumefantrine.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Tamsulosin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Mannitol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Mecamylamine.Approved, Investigational
MedetomidineTamsulosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineTamsulosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
MetaraminolTamsulosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Tamsulosin can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Tamsulosin.Approved
MethotrimeprazineThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MethoxamineTamsulosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineTamsulosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Methyclothiazide.Approved
MethyldopaTamsulosin may decrease the vasoconstricting activities of Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tamsulosin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Tamsulosin is combined with Mibefradil.Investigational, Withdrawn
MidodrineTamsulosin may decrease the vasoconstricting activities of Midodrine.Approved
MidostaurinThe serum concentration of Tamsulosin can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Tamsulosin can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Minoxidil.Approved, Investigational
MirabegronThe metabolism of Tamsulosin can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Tamsulosin.Investigational
MitotaneThe serum concentration of Tamsulosin can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tamsulosin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Tamsulosin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Tamsulosin.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
NaftopidilThe risk or severity of hypotension can be increased when Tamsulosin is combined with Naftopidil.Investigational
NaphazolineTamsulosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
NefazodoneThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Tamsulosin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Tamsulosin can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Tamsulosin can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Niguldipine.Experimental
NilotinibThe metabolism of Tamsulosin can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tamsulosin.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Tamsulosin.Approved, Investigational
NorepinephrineTamsulosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTamsulosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinTamsulosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tamsulosin.Approved, Investigational
OctopamineTamsulosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlaparibThe metabolism of Tamsulosin can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Olmesartan.Approved, Investigational
OlodaterolTamsulosin may decrease the vasoconstricting activities of Olodaterol.Approved
OrciprenalineTamsulosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Tamsulosin can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Tamsulosin is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
OxyfedrineTamsulosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTamsulosin may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamsulosin.Approved, Vet Approved
PalbociclibThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Tamsulosin can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Papaverine.Approved, Investigational
ParoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
PentobarbitalThe metabolism of Tamsulosin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tamsulosin.Approved
PhenobarbitalThe metabolism of Tamsulosin can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tamsulosin.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Tamsulosin.Approved
PhenylephrineTamsulosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTamsulosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Tamsulosin can be increased when combined with Phenytoin.Approved, Vet Approved
PinaveriumThe risk or severity of hypotension can be increased when Tamsulosin is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tamsulosin.Approved, Investigational
PirbuterolTamsulosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PitolisantThe serum concentration of Tamsulosin can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
PosaconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tamsulosin.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Tamsulosin.Approved
PrenalterolTamsulosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Tamsulosin can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolTamsulosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineThe metabolism of Tamsulosin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tamsulosin.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
PseudoephedrineTamsulosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Tamsulosin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Tamsulosin can be decreased when combined with Quinine.Approved
RacepinephrineTamsulosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineTamsulosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Ramipril.Approved
RanolazineThe metabolism of Tamsulosin can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tamsulosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tamsulosin.Approved
ReproterolTamsulosin may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Tamsulosin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Tamsulosin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tamsulosin can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineTamsulosin may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolTamsulosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Riociguat.Approved
RisperidoneTamsulosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronTamsulosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTamsulosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Tamsulosin can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineTamsulosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Tamsulosin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tamsulosin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tamsulosin.Approved
RucaparibThe metabolism of Tamsulosin can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tamsulosin.Approved
SalbutamolTamsulosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTamsulosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Tamsulosin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tamsulosin.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Tamsulosin is combined with Seletracetam.Investigational
SertralineThe metabolism of Tamsulosin can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tamsulosin.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
SilodosinTamsulosin may increase the antihypertensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Tamsulosin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Tamsulosin can be increased when it is combined with Simeprevir.Approved
SolabegronTamsulosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Tamsulosin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Tamsulosin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.Approved, Investigational
SulfisoxazoleThe metabolism of Tamsulosin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SynephrineTamsulosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
TelaprevirThe serum concentration of Tamsulosin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Telmisartan.Approved, Investigational
TerazosinTamsulosin may increase the antihypertensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Tamsulosin can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTamsulosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerodilineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
ThioridazineThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.Approved, Withdrawn
TiclopidineThe metabolism of Tamsulosin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
TipranavirThe serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTamsulosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tolfenamic Acid.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolTamsulosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Triamterene.Approved
TrimazosinTamsulosin may increase the antihypertensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Tamsulosin is combined with Trimethadione.Approved
TulobuterolTamsulosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
UrapidilTamsulosin may increase the antihypertensive activities of Urapidil.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Tamsulosin.Approved
VemurafenibThe serum concentration of Tamsulosin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Tamsulosin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Tamsulosin can be decreased when combined with Verapamil.Approved
VinpocetineThe risk or severity of hypotension can be increased when Tamsulosin is combined with Vinpocetine.Investigational
VoriconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Voriconazole.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Tamsulosin is combined with WIN 55212-2.Experimental
XamoterolTamsulosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineTamsulosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Ziconotide.Approved
ZiprasidoneThe metabolism of Tamsulosin can be decreased when combined with Ziprasidone.Approved
ZonisamideThe risk or severity of hypotension can be increased when Tamsulosin is combined with Zonisamide.Approved, Investigational
Food Interactions
  • Take 30 minutes after a meal (always after the same meal). Taking the drug with food minimizes plasma levels variations.

References

Synthesis Reference

Hun Wang, Jun Park, Min Kwon, Ji Shim, Bong Lee, Hong Jeon, "Controlled release formulation of tamsulosin hydrochloride and preparation process thereof." U.S. Patent US20050100606, issued May 12, 2005.

US20050100606
General References
  1. Dunn CJ, Matheson A, Faulds DM: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61. [PubMed:11950378]
  2. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ: Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs. 2002;62(1):135-67. [PubMed:11790159]
  3. Wilt TJ, Mac Donald R, Rutks I: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081. [PubMed:12535426]
External Links
Human Metabolome Database
HMDB0014844
KEGG Compound
C07124
PubChem Compound
129211
PubChem Substance
46507763
ChemSpider
114457
BindingDB
50060964
ChEBI
9398
ChEMBL
CHEMBL836
Therapeutic Targets Database
DAP000086
PharmGKB
PA451583
IUPHAR
488
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tamsulosin
ATC Codes
G04CA02 — TamsulosinG04CA53 — Tamsulosin and solifenacinG04CA52 — Tamsulosin and dutasteride
AHFS Codes
  • 12:16.04.12 — Selective Alfa-1-adrenergic Blocking Agents
FDA label
Download (248 KB)
MSDS
Download (20.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionInguinal Hernias / Urinary Retention1
1CompletedNot AvailableBenign Prostatic Hyperplasia (BPH)1
1CompletedNot AvailableCardiovascular / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceBenign Prostatic Hyperplasia (BPH) / Healthy Volunteers / Lower Urinary Tract Symptoms (LUTS) / Phase 11
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceEC905 / Healthy Volunteers / Multiple Dose / Pharmacokinetics1
1CompletedBasic ScienceEC905 / Healthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherUrologic Diseases2
1CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Erectile Dysfunction (ED)1
1CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Healthy Volunteers1
1CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / LUTS / Overactive Bladder1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentErectile Dysfunction (ED) / Prostatic Hyperplasia2
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHealty Male Volunteers1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1CompletedTreatmentProstatic Hyperplasia8
1CompletedTreatmentUrination Disorders1
1, 2Not Yet RecruitingTreatmentDiabetic Macular Edema (DME)1
1, 2Unknown StatusTreatmentNeurogenic Bladder Dysfunction1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)2
2CompletedTreatmentBladder Outlet Obstruction / Lower Urinary Tract Symptoms (LUTS)1
2CompletedTreatmentLower Urinary Tract Symptoms (LUTS)2
2CompletedTreatmentLower Urinary Tract Symptoms (LUTS) / Prostatic Hyperplasia1
2CompletedTreatmentNeurogenic Bladder Dysfunction1
2CompletedTreatmentProstate Hyperplasia1
2CompletedTreatmentProstatic Hyperplasia1
2RecruitingPreventionUrinary Retention1
2RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Track Symptoms1
2Unknown StatusTreatmentUpper Tract Ureterolithiasis1
2, 3CompletedTreatmentLower Urinary Tract Symptoms (LUTS) / Overactive Bladder1
2, 3CompletedTreatmentNeurogenic Bladder Dysfunction1
3Active Not RecruitingPreventionUrinary Retention / Urinary Tract Infections (UTIs)1
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH)6
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Erectile Dysfunction (ED) / Prostatic Hyperplasia1
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS)1
3CompletedTreatmentNon-oncological Indication to Ureteral Stenting1
3CompletedTreatmentProstatic Hyperplasia2
3CompletedTreatmentRectal Carcinoma / Urinary Retention1
3CompletedTreatmentUreteral Calculus / Ureterolithiasis1
3CompletedTreatmentUrological Manifestations1
3RecruitingPreventionPostoperative Urinary Retention2
3RecruitingTreatmentBenign Prostatic Hyperplasia (BPH)1
3RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Erectile Dysfunction (ED)1
3RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS)1
3TerminatedTreatmentBenign Prostatic Hyperplasia (BPH)1
3TerminatedTreatmentBenign Prostatic Hyperplasia (BPH) / Chronic Prostatitis (CP)1
3TerminatedTreatmentUrinary Retention1
3Unknown StatusTreatmentHyperplasia1
3Unknown StatusTreatmentLower Urinary Tract Symptoms (LUTS)1
3Unknown StatusTreatmentRenal Stones1
3WithdrawnTreatmentRenal Stones1
4Active Not RecruitingTreatmentBenign Prostatic Hyperplasia (BPH)1
4Active Not RecruitingTreatmentCalcium Nephrolithiasis / Ureterolithiases1
4Active Not RecruitingTreatmentUreteral Obstruction1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Benign Prostatic Hypertrophy (BPH) / Overactive Bladder1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS) / Overactive Bladder1
4CompletedTreatmentProstatic Hyperplasia5
4CompletedTreatmentRelieve of Ureteral Stent Symptoms1
4CompletedTreatmentUrinary Incontinence (UI)1
4Enrolling by InvitationPreventionPostoperative Urinary Retention1
4Enrolling by InvitationTreatmentCalcium Nephrolithiasis1
4Not Yet RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Overactive Bladder1
4RecruitingPreventionHernia / Urinary Retention1
4RecruitingPreventionPostoperative Urinary Retention1
4RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Overactive Bladder1
4RecruitingTreatmentBladder Cancers1
4RecruitingTreatmentCalcium Nephrolithiasis1
4TerminatedTreatmentProstatic Hyperplasia1
4TerminatedTreatmentUreteral Calculus / Ureteral Stones / Ureterolithiasis1
4Unknown StatusTreatmentNeurogenic Lower Urinary Tract Dysfunction1
4Unknown StatusTreatmentNocturia1
4Unknown StatusTreatmentRenal Colic1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
Not AvailableCompletedNot AvailableProstatic Hyperplasia6
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentCalcium Nephrolithiasis / Ureteral Calculus1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableCompletedTreatmentRenal Stones / Ureteral Stones1
Not AvailableCompletedTreatmentUreteral Calculus1
Not AvailableNot Yet RecruitingTreatmentDisorder of Urinary Stent1
Not AvailableRecruitingTreatmentProstate Cancer1
Not AvailableTerminatedPreventionPostoperative Urinary Retention1
Not AvailableTerminatedTreatmentUrolithiasis1
Not AvailableUnknown StatusScreeningRenal Stones1
Not AvailableUnknown StatusTreatmentBenign Prostatic Hyperplasia (BPH)2
Not AvailableUnknown StatusTreatmentChronic Kidney Failure / Prostatic Hyperplasia1
Not AvailableUnknown StatusTreatmentProstatic Neoplasms, Prostatectomy1
Not AvailableUnknown StatusTreatmentProstatitis1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Synthon pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
  • Actavis Group
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Astellas Pharma Inc.
  • Atlantic Biologicals Corporation
  • Boehringer Ingelheim Ltd.
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Diversified Healthcare Services Inc.
  • GlaxoSmithKline Inc.
  • Global Pharmaceuticals
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Mylan
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Stat Rx Usa
  • Synthon Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Wockhardt Ltd.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, extended releaseOral0.4 mg
CapsuleOral
Capsule, extended releaseOral
CapsuleOral.4 mg/1
Capsule, gelatin coatedOral.4 mg/1
Capsule, extended releaseOral0.4 mg
Prices
Unit descriptionCostUnit
Flomax 0.4 mg capsule4.71USD capsule
Tamsulosin hcl 0.4 mg capsule4.3USD capsule
Flomax Cr 0.4 mg Extended-Release Tablet0.63USD tablet
Mylan-Tamsulosin 0.4 mg Sustained-Release Capsule0.63USD capsule
Novo-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ran-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ratio-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Sandoz Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4703063No1993-04-272010-04-27Us
CA2490299No2008-08-262023-12-24Canada
CA2144077No2005-05-242013-09-10Canada
US5565467No1995-11-202015-11-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226-228 °C (HCl salt)Not Available
water solubilitySparingly soluble in waterNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP3.05ALOGPS
logP2.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)9.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity108.86 m3·mol-1ChemAxon
Polarizability43.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.5915
Caco-2 permeable-0.6473
P-glycoprotein substrateSubstrate0.5911
P-glycoprotein inhibitor INon-inhibitor0.5734
P-glycoprotein inhibitor IINon-inhibitor0.5522
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6012
CYP450 1A2 substrateNon-inhibitor0.7876
CYP450 2C9 inhibitorInhibitor0.5916
CYP450 2D6 inhibitorNon-inhibitor0.8614
CYP450 2C19 inhibitorNon-inhibitor0.5056
CYP450 3A4 inhibitorInhibitor0.718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6146
Ames testNon AMES toxic0.6245
CarcinogenicityNon-carcinogens0.6419
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4091 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.6971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Benzenesulfonamides / Phenylpropanes / Benzenesulfonyl compounds / Phenoxy compounds / Methoxybenzenes / Anisoles / Aralkylamines / Alkyl aryl ethers / Organosulfonamides / Aminosulfonyl compounds
show 4 more
Substituents
Amphetamine or derivatives / Benzenesulfonamide / Benzenesulfonyl group / Phenylpropane / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Aralkylamine
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfonamide (CHEBI:9398)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96. [PubMed:9352698]
  3. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165]
  4. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700]
  5. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67. [PubMed:8647141]
  6. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54. [PubMed:8647140]
  7. Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. doi: 10.1016/j.mehy.2009.02.022. Epub 2009 May 8. [PubMed:19427736]
  8. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8. [PubMed:9117115]
  3. Lowe FC: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13-21. [PubMed:16986050]
  4. Tomiyama Y, Tatemichi S, Tadachi M, Kobayashi S, Hayashi M, Kobayashi M, Yamazaki Y, Shibata N: [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:225-30. [PubMed:16518087]
  5. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758]
  6. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174]
  7. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758]
  2. Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719]
  3. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174]
  4. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997 Sep 15;33(1):55-9. [PubMed:9294627]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Matsushima H, Watanabe T, Higuchi S: Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J Pharm Sci. 2000 Apr;89(4):490-8. [PubMed:10737910]
  2. Hanada K, Tochikura N, Ogata H: Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Biol Pharm Bull. 2007 Aug;30(8):1593-5. [PubMed:17666829]
  3. Koiso K, Akaza H, Kikuchi K, Aoyagi K, Ohba S, Miyazaki M, Ito M, Sueyoshi T, Matsushima H, Kamimura H, Watanabe T, Higuchi S: Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol. 1996 Nov;36(11):1029-38. [PubMed:8973992]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:02